Last updated July 18, 2026
Key finding
EPL treatment significantly reduced CAP (p = 0.0269) versus placebo.
This study investigated the effects of essential phospholipids on liver health in patients with metabolic dysfunction-associated steatotic liver disease, finding significant improvements in hepatic steatosis and quality of life.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
High Risk
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of essential phospholipids on liver health in patients with metabolic dysfunction-associated steatotic liver disease, finding significant improvements in hepatic steatosis and quality of life.
These findings highlight the potential of essential phospholipids as a therapeutic option for patients suffering from metabolic dysfunction-associated steatotic liver disease. Improved liver health and quality of life can lead to better management of this condition, which is increasingly prevalent and associated with significant health risks.
Limited sample size may affect generalizability. Short duration of follow-up may not capture long-term effects. Potential for unmeasured confounding factors.
Published in
Publication details and source links for this paper.
Norbert S, Marek H, Jiangao F, et al. The beneficial effects of essential phospholipids on liver health in patients with metabolic dysfunction-associated steatotic liver disease. Liver International. 2026;46(5):e70601. doi:10.1111/liv.70601
EPL treatment significantly reduced hepatic steatosis (CAP score) by -1.5 dB/m (p = 0.0269).
Quality of life improved with a 0.5 score increase in fatigue subscore (p = 0.0229) with EPL.
EPL significantly reduced HbA1c levels by -0.5% (p = 0.0069).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Essential Phospholipids (EPL) and Controlled attenuation parameter, HbA1c, Quality of life.
This study contributes evidence to
Primary intervention
Essential Phospholipids (EPL)
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
3
Evidence pairs
310
Related studies
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence topic
matched_outcome
Core evidence
The primary outcomes reported in this study.
Essential Phospholipids (EPL) → Controlled attenuation parameter
Essential Phospholipids (EPL) → Controlled attenuation parameter
Essential Phospholipids (EPL) → Quality of life
Essential Phospholipids (EPL) → Quality of life
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Essential Phospholipids (EPL) and Controlled attenuation parameter, Essential Phospholipids (EPL) and HbA1c.
This study contributes to the evidence on the following intervention-outcome relationships.
Supplements
Curated evidence collections and hubs this study is part of.
All studies measuring Controlled attenuation parameter
Measures Controlled attenuation parameter as a key outcome.
All studies on Essential Phospholipids (EPL)
Contributes to Essential Phospholipids (EPL) evidence base.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies measuring Quality of Life Outcomes
Measures Quality of Life Outcomes as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Essential Phospholipids (EPL) appears to improve Controlled attenuation parameter.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Controlled attenuation parameter
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Essential Phospholipids (EPL) appears to improve HbA1c.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
HbA1c
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Essential Phospholipids (EPL) for Quality of life.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Quality of life
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
